Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Effect of breathing phase number on the 4D robust optimization for pancreatic cancer intensity modulated proton therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : BioMed Central, [2001-
    • الموضوع:
    • نبذة مختصرة :
      Purpose: Respiratory movement, as one of the main challenges in proton therapy for pancreatic cancer patients, could not only lead to harm to normal tissues but also lead to failure of the tumor control, resulting in irreversible consequences. Including respiratory movements into the plan optimization, i.e. 4D robust optimization, may mitigate the interplay effect. However, 4D robust optimization considering images of all breathing phases is time-consuming and less efficient. This work aims to investigate the effect of the breathing phase number on the 4D robust optimization for pancreatic cancer intensity modulated proton therapy (IMPT) by examining plan quality and computational efficiency.
      Methods: A total of 15 pancreatic cancer patients were retrospectively analyzed. In this study, both anterior-fields and posterior-fields plans were created for each patient. For each plan, six four-dimensional (4D) robust treatment planning strategies with different numbers of respiratory phases and one three-dimensional (3D) treatment plan were created. Optimization of the plans were performed on all ten phases (10phase plan), two extreme phases (2phase plan), two extreme phases plus an intermediate state (3phase plan), two extreme phases plus the 3D CT (3Aphase plan), six phases during the exhalation stage (6Exphase plan), six phases during the inhalation stage (6Inphase plan) and 3D Computed Tomography (CT) scan image (3D plan), respectively. 4D dynamic dose (4DDD) was then calculated to access the interplay effect by considering respiratory motion and dynamic beam delivery. Plan quality and dosimetric parameters for the target and organs at risk (OARs) were then analyzed.
      Results: Compared to the 4D plans, 3D plan performed terribly in terms of target coverage and organs at risk. Target dose in anterior-fields plan varied slightly among all six 4D treatment planning strategies. Both the 6Exphase and 6Inphase plans demonstrated performance that was comparable to the 10phase plan in target coverage, outperforming the other five plans for anterior-fields plan. It's basically the same for the posterior-fields plan. The six strategies showed similar OARs sparing effect for both anterior-fields and posterior-fields plan. Compared with the 10phase plan, the average decline rates of the optimization time of the six plans of 2phase, 3phase, 3Aphase, 6Exphase, 6Inphase, and 3D were 73.26 ± 6.54% vs. 74.48 ± 6.63%, 65.80 ± 7.89% vs. 65.81 ± 9.58%, 54.67 ± 11.52% vs. 65.75 ± 9.58%, 42.14 ± 13.57% vs. 39.63 ± 16.93%, 37.72 ± 11.70% vs. 40.79 ± 13.62% and 75.52 ± 8.21% vs. 80.67 ± 5.62%, respectively (anterior vs. posterior). With the decrease of the number of phases selected for optimization, the decline rates increased, while the other dosimetry parameters generally showed a deterioration trend.
      Conclusion: In this study, a comprehensive evaluation of six 4D robust treatment planning strategies and one 3D treatment planning strategy for pancreatic cancer patients receiving IMPT was performed. The results showed that six 4D robust optimization strategies were comparable in common posterior field therapy. 2phase and 3phase (including 3Aphase) treatment planning strategies could replace the 10phase treatment planning strategy. It should be noted that patients with large motion amplitudes should receive special attention. The dosimetric performance of the 6Exphase and 6Inphase plans closely aligned with that of the 10phase plan in anterior fields. These plans offered a feasible alternative to 10phase treatment planning strategy by reducing optimization time while maintaining dose coverage of the target and protection of OARs. This research provides guidelines to reduce optimization time and improve clinical efficiency for pancreatic cancer IMPT.
      (© 2024. The Author(s).)
    • References:
      Front Oncol. 2020 Oct 09;10:574605. (PMID: 33163404)
      Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):41-50. (PMID: 28816159)
      Med Phys. 2010 Feb;37(2):449-60. (PMID: 20229853)
      Clin Cancer Res. 2022 Dec 1;28(23):5167-5179. (PMID: 36129461)
      Radiat Oncol. 2018 Jun 25;13(1):120. (PMID: 29941049)
      Phys Med Biol. 2010 Sep 7;55(17):5103-21. (PMID: 20702927)
      Front Oncol. 2022 Jan 04;11:836410. (PMID: 35059321)
      Adv Radiat Oncol. 2018 Apr 13;3(3):314-321. (PMID: 30202800)
      Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1231-9. (PMID: 8262852)
      Front Oncol. 2021 Sep 22;11:747532. (PMID: 34631584)
      Cancers (Basel). 2022 Jun 04;14(11):. (PMID: 35681769)
      Med Phys. 2018 Jul 16;:. (PMID: 30014478)
      Med Phys. 2014 Aug;41(8):081711. (PMID: 25086521)
      Phys Med. 2022 Nov;103:1-10. (PMID: 36182764)
      CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204)
      Phys Med. 2021 Nov;91:62-72. (PMID: 34715550)
      Med Phys. 2007 Jan;34(1):233-45. (PMID: 17278509)
      Radiother Oncol. 2009 Aug;92(2):238-43. (PMID: 19454367)
      Front Oncol. 2022 Mar 09;12:806153. (PMID: 35356213)
      Adv Radiat Oncol. 2021 Jul 29;6(6):100757. (PMID: 34604607)
      Cancers (Basel). 2023 Apr 29;15(9):. (PMID: 37174016)
      Phys Med Biol. 2011 Aug 21;56(16):R113-44. (PMID: 21775795)
      Radiother Oncol. 2021 Jan;154:60-69. (PMID: 32861703)
      Med Phys. 2011 Mar;38(3):1672-84. (PMID: 21520880)
      Pract Radiat Oncol. 2020 May - Jun;10(3):e136-e146. (PMID: 31761541)
      Cancer Radiother. 2022 Feb-Apr;26(1-2):259-265. (PMID: 34953706)
      Strahlenther Onkol. 2012 Jan;188(1):97-9. (PMID: 22234506)
      Med Phys. 2019 Dec;46(12):5434-5443. (PMID: 31595521)
      J Radiat Res. 2016 Aug;57 Suppl 1:i53-i57. (PMID: 27029741)
      Cancer Lett. 2019 May 1;449:1-7. (PMID: 30771429)
      Lancet Oncol. 2012 Sep;13(9):e383-91. (PMID: 22935238)
    • Grant Information:
      12105160 National Natural Science Foundation of China; 82072094 National Natural Science Foundation of China; ZR2021QA099 Natural Science Foundation of Shandong Province; ZR2019LZL017 Natural Science Foundation of Shandong Province; ts201712098 Taishan Scholar Project of Shandong Province; 2022B03019-5 Xinjiang Uygur Autonomous Region key research and development project; 2021HZ81 Tumor precision radiotherapy peak plan
    • Contributed Indexing:
      Keywords: 4D dynamic dose; 4D robust optimization; Intensity modulated Proton Therapy; Pancreatic cancer
    • الموضوع:
      Date Created: 20241031 Date Completed: 20241031 Latest Revision: 20241102
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC11526620
    • الرقم المعرف:
      10.1186/s12885-024-13094-9
    • الرقم المعرف:
      39478463